Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Scientists used generative AI to build an entirely new class of RNA transporters called Synthetic Transfer Vehicles (STVs). The lead candidate, STV-C8, outperformed lipid nanoparticles in cell culture and successfully delivered CRISPR components in animal models — with no signs of immune or toxic side effects. It could reshape how RNA-based therapies, including gene editors, reach their targets.
Researchers at Helmholtz Munich and the Technical University of Munich have created a brand-new class of RNA delivery vehicles — called Synthetic Transfer Vehicles (STVs) — by combining natural protein building blocks with AI-designed synthetic protein structures. Unlike existing delivery systems such as lipid nanoparticles or viral vectors, STVs are built from the ground up with non-natural geometries, giving scientists far more design flexibility.
The standout candidate, STV-C8, significantly outperformed lipid nanoparticles in cell culture, requiring substantially less RNA to achieve comparable protein production. In mice, intravenous STV-C8 drove RNA expression primarily in the lungs with no detectable immune or toxic side effects. In pigs, the team loaded STV-C8 with CRISPR/Cas9 components and successfully edited the dystrophin gene — the gene disrupted in Duchenne muscular dystrophy.
Key Takeaways:
Why it matters: Current RNA delivery tools have real limitations in efficiency and selectivity. STV-C8 represents a potentially transformative platform for RNA therapeutics and gene editing, with implications for diseases like Duchenne muscular dystrophy and beyond.
